ClinicalTrials.gg
RecruitingNCT07422597PRORANDUpdated Oct 21, 2026

Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer

An interventional study of European Study of screening for prostate cancer risk calculator in Prostate Cancer, sponsored by Norwegian University of Science and Technology. Recruiting at 3 sites in Norway. Open to male participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,016
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Prostatic Neoplasms with a site in Norway — 16 open to participants now, 27 under way, 9 of them phase 3. Prostatic Neoplasms · Norway.

Planned enrollment
12th of 66
1,016 · median 383
Started
2026
with 1 other
No phase
23 of 85
4 open now
Primary completion
2027-12
later than 14 of 26 live
Registered
84th of 85
by date
Lead sponsor
6 of 85
Norwegian University of Science and Technology

Among the 85 studies in Prostatic Neoplasms with a site in Norway, this one is the 12th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 14 of the 26 other live ones, and was the 84th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

16 of the 85 studies in Prostatic Neoplasms with a site in Norway are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 50 Years to 75 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Prostatic Neoplasms with a site in Norway, or all of them as a file.
02

Study summary

Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary. In others, the test is sufficiently elevated that men are referred for further investigations. Most men with an elevated PSA are offered an MRI examination of the prostate gland, and for some, a tissue sample of the prostate is also recommended if the suspicion of cancer is high enough. Although this comprehensive investigation reveals most clinically significant , or dangerous cases of cancer, many indolent, or "harmless" cancer cases are also detected, which would not have caused the man any harm during his lifetime (approximately 20% of all prostate cancer diagnoses diagnosed in current clinical practive). Cancer treatment is not recommended for such cases, but for many men, the diagnosis and subsequent follow-up can cause him and his family anxity and concern. In addition, prostate biopsies are unpleasant for the patient and the investigation process is resource-intensive for both the man and the health care service.

Risk stratification uses machine learning methods to better identify the men who require further investigations with MRI and tissue samples. In this project, the investigators investigate whether the best risk stratification tools are non-inferior in detecting clinically significant prostate cancer compared to current practice, and whether they lead to fewer tissue samples, MRI scans, less health anxiety, and better cost-effectiveness.

Read the detailed description

Background Prostate cancer (PCa) is the most common non-skin cancer among men. Most PCa cases are identified after an elevated prostate-specific antigen (PSA) level has been identified on blood testing. In most men this leads to a hospital referral, magnetic resonance imaging (MRI) of the prostate, and biopsy (tissue sampling) of the prostate in men where MRI is suggestive of a prostate cancer.

Although the PSA-test is the main method for identifying men who have prostate cancer, the test has low specificity, meaning that many men with an elevated PSA-level do not harbour PCa that will cause the man harm within his lifetime. In current clinical practice, such "false" PSA elevations can be difficult to distinguish from the "true" elevations found in men with clinically significant PCa (csPCa, Gleason >3+3) and therefore still lead to an MRI, and in many cases even a biopsy procedure is necessary to exclude csPCa.

Multivariable risk stratification uses the statistical methods of machine learning to quantify a man's probability of having prostate cancer based on other information that is available about the patient, which is known to affect the likelihood of him having prostate cancer. The aim of such stratification is to improve the identification of men who are likely to have prostate cancer, beyond the capacity of the unspecific PSA test, with its many false positives. This in order to improve identification of men who actually need further diagnostic testing, and to better distinguish these men from those men where the probability of significant disease is so low that further investigations can safely be omitted, without missing cases of significant disease.

Although such risk stratification tools have previously been developed, are readily available, and in retrospective studies have been demonstrated to reduce unnecessary MRIs and biopsies considerably, clinical uptake continues to be low due to the lack of prospective trials demonstrating efficacy and safety. As a result, at present, almost all men referred with a suspicion of prostate cancer undergo MRI and subsequent clinical assessment for biopsy. In health care settings where PCa-screening is implemented, as is a stated goal in the EU Council cancer screening guidelines, the number of men requiring diagnostic work-up will likely increase dramatically in ensuing years.

Knowledge gaps The risk calculators (RCs) stemming from the European Randomised Study of Screening for Prostate Cancer (ERSPC) are the currently best known and most utilised multivariable risk stratification tools. Their use has been retrospectively validated in multiple studies. All presently available development, and almost all validating studies are, however, hampered by their retrospective design and varying size which presently hinder widespread clinical implementation of this promising new method. In the only prospective study known to us, 47% of MRI investigations could be avoided compared with today's practice of performing an MRI in all men referred with an elevated PSA (>3ng/ml). However, this study was not designed to answer the primary research question of the present proposal, namely whether this RC approach gives csPCa detection that is non-inferior to performing an MRI in all referred men. As a result, although multivariable risk stratification of men with suspected PCa holds promise, whether the method gives non-inferior cancer detection to current practice represents a key knowledge gap which presently limits its implementation.

Study aims The primary objective of the current proposal is to perform the first prospective, adequately powered investigation of whether risk stratification using the risk stratification calculators from the European Randomised Study of Screening for Prostate Cancer study gives non-inferior detection of clinically significant prostate cancer compared with performing an MRI in all men referred with a suspicion of prostate cancer.

How clinical decision-making in men suspected of harbouring PCa affects men's health-related quality of life also has not been thoroughly investigated. And similarly, whether multivariable risk stratification is in fact cost-efficient compared with an MRI-all approach has not been conclusively determined in a prospective, clinical trial. The secondary aims of the study are to examine how the decision of whether to perform biopsy affects the health-related quality of life of men who undergo such consideration, and to prospectively determine the cost-efficiency of performing multivariable risk stratification, compared with performing an MRI in all men referred with a suspicion of prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Suspected prostate cancer
  • Elevated PSA
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • more than 10 years remaining
  • Suspected localized prostate cancer
  • Suspicious DRE (cT2)
  • PSA 3-20 ng/ml

Exclusion criteria

Exclusion Criteria:

  • cT3 and/or cT4 (on DRE)
  • PSA >20 ng/ml
  • Prior diagnosis of prostate cancer
  • to MRI or to prostate
  • Medications known to affect serum PSA levels
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,016 participants (estimated)

Study arms

  • Experimental
    Upfront MRI and Multivariable risk assessment in all men

    Single group

    Device: European Study of screening for prostate cancer risk calculator

Interventions

  • DeviceEuropean Study of screening for prostate cancer risk calculator

    The ERSPC RCs are the currently best known and most utilised multivariable PCa risk stratification tools. All participating men undergo risk stratification by ERSPC RCs to determine need for MRI and for biopsy.

    Also known as: https://www.prostatecancer-riskcalculator.com/, Rotterdam prostate cancer risk calculator

06

What researchers measure

Primary outcomes

  1. Detection of clinically significant prostate cancer

    The study examines whether the risk calculator strategy gives non-inferior detection of csPCa compared with performing an MRI upfront in all men. csPCa defined as International society of Urological pathology grade group (ISUP GG) \>1.

    Time frame: During the initial diagnostic work-up (up to 6 weeks)

Secondary outcomes

  1. Detection of clinically insignificant prostate cancer

    The investigators will compare the number of patients with low grade (ISUP GG 1) prostate cancer detected by the upfront MRI vs upfront RC strategies

    Time frame: During the initial diagnostic work-up (up to 6 weeks)

  2. Numbers of prostate biopsy sessions required

    Determine the number of prostata biopsy sessions required by the upfront MRI vs upfront RC strategies

    Time frame: 1 year after completion of inclusion

  3. Numbers of prostate MRIs required

    Determine the number of prostate MRI scans required by the upfront MRI vs upfront RC strategies

    Time frame: 1 year after completion of inclusion

  4. Quality of life effect of decision to perfrom prostate biopsy

    The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 form. The EORTC QLQ-C30 (v3.0) scores 30 items into 5 functional scales, 9 symptom scales/items, and global health status (0-100 range). Higher scores indicate better functioning/QoL but worse symptoms.

    Time frame: 1 year after study inclusion is completed

  5. Quality of life effect of decision to perfrom prostate biopsy

    The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: IPSS (International Prostate Symptom Score). Higher scores mean more symptoms. IPSS classifies symptoms as mild (0-7), moderate (8-19), or severe (20-35)

    Time frame: 1 year after study inclusion is completed

  6. Quality of life effect of decision to perfrom prostate biopsy

    The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: IIEF-5 (International Index of Erectile Function) Lower IIEF-5 scores mean higher degree of erectile dysfunction

    Time frame: 1 year after study inclusion is completed

  7. Quality of life effect of decision to perfrom prostate biopsy

    The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Participants will be asked whether they are concerned about the possibility that they may have prostate cancer (yes/no), and about how concerned about the posibility they have cancer (no concerns, mild concerns, moderate concerns, severe concerns).

    Time frame: 1 year after study inclusion is completed

  8. Cost-effectiveness assessment

    Determine cost-effectivenes of upfront MRI vs upfront RC. The investigators will determine the incremental cost-effectiveness ratio (ICER) and the net monetary benefit (NMB)

    Time frame: 1 year after completion of inclusion

  9. Perilesional biopsy results

    Targeted biopsies will be taken from PI-RADS 3-5 lesions on MRI. Additional biopsies are to be taken from the area of prostate surrounding the lesion in the prostate seen on MRI, as per current European Urological Association guidelines. The study will assess the value of perilesional biopsies by recording the detection of prostate cancer in such perilesional biopsies.

    Time frame: During the initial diagnostic work up (up to 6 weeks)

  10. Quality of life effect of decision to perfrom prostate biopsy

    The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: The Memorial Anxiety Scale for Prostate Cancer (MAX-PC). An 18-item, validated questionnaire designed to measure cancer-specific anxiety in men, specifically covering prostate cancer anxiety, prostate-specific antigen sampling anxiety, and fear of cancer recurrence. Higher scores mean higher degree of anxiety relating to prostate cancer and to prostate-specific antigen testing.

    Time frame: 1 year after study inclusion is completed.

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Straat KRV, Hagens MJ, Cools Paulino Pereira LJ, van den Bergh RCN, Mazel JW, Noordzij MA, Rynja SP. Risk Calculator Strategy Before Magnetic Resonance Imaging Stratification for Biopsy-naive Men with Suspicion for Prostate Cancer: A Cost-effectiveness Analysis. Eur Urol Open Sci. 2024 Oct 14;70:52-57. doi: 10.1016/j.euros.2024.08.017. eCollection 2024 Dec. PubMed 39483520 ↗
  • Sharp L, Morgan E, Drummond FJ, Gavin A. The psychological impact of prostate biopsy: Prevalence and predictors of procedure-related distress. Psychooncology. 2018 Feb;27(2):500-507. doi: 10.1002/pon.4521. Epub 2017 Oct 11. PubMed 28766309 ↗
  • Coyle C, Morgan E, Drummond FJ, Sharp L, Gavin A. Do men regret prostate biopsy: Results from the PiCTure study. BMC Urol. 2017 Jan 26;17(1):11. doi: 10.1186/s12894-016-0194-y. PubMed 28125998 ↗
  • Reesink DJ, Schilham MGM, van der Hoeven EJRJ, Schoots IG, van Melick HHE, van den Bergh RCN. Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy. World J Urol. 2021 Jul;39(7):2453-2461. doi: 10.1007/s00345-020-03488-2. Epub 2020 Oct 22. PubMed 33090259 ↗
  • Davik P, Remmers S, Elschot M, Roobol MJ, Bathen TF, Bertilsson H. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification. BJUI Compass. 2022 Apr 22;3(5):344-353. doi: 10.1002/bco2.146. eCollection 2022 Sep. PubMed 35950035 ↗
  • Davik P, Elschot M, Frost Bathen T, Bertilsson H. Repeat Prostate-specific Antigen Testing Improves Risk-based Selection of Men for Prostate Biopsy After Magnetic Resonance Imaging. Eur Urol Open Sci. 2024 Jun 13;65:21-28. doi: 10.1016/j.euros.2024.05.011. eCollection 2024 Jul. PubMed 38974460 ↗
  • Patel HD, Remmers S, Ellis JL, Li EV, Roobol MJ, Fang AM, Davik P, Rais-Bahrami S, Murphy AB, Ross AE, Gupta GN. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk. JAMA Netw Open. 2024 Mar 4;7(3):e241516. doi: 10.1001/jamanetworkopen.2024.1516. PubMed 38451522 ↗
  • Davik P, Remmers S, Elschot M, Roobol MJ, Bathen TF, Bertilsson H. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres. BJU Int. 2024 Mar;133(3):278-288. doi: 10.1111/bju.16163. Epub 2023 Sep 12. PubMed 37607322 ↗
  • Hofmann B, Haug ES, Andersen ER, Kjelle E. Increased magnetic resonance imaging in prostate cancer management-What are the outcomes? J Eval Clin Pract. 2023 Sep;29(6):893-902. doi: 10.1111/jep.13791. Epub 2022 Nov 14. PubMed 36374190 ↗
  • Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19;98(8):529-34. doi: 10.1093/jnci/djj131. PubMed 16622122 ↗

Individual participant data

Plan to share: Yes — Sharing of anonmous data for scientific purposeswill be considered upon reasonable request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 21 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Feb 20, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07422597
Collaborators
Norwegian Cancer Society
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Petter Davik, MD, PhD
Contact
petter.davik@ntnu.no
+47 72829919
Joakim S Lund, MD
Contact
Joakim.Schistad.Lund@stolav.no
+4772574142
Petter Davik, MD, PhD
principal investigator · Norwegian University of Science and Technology (NTNU)
Magnus Steigedal, PhD
study chair · Norwegian University of Science and Technology, Head of Department (IKOM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion